Neoadjuvan Kemoradyoterapi Uygulanan Yaşlı Rektum Kanserli Hastalarda Sağkalımı Etkileyen Faktörler

MERYEM AKTAN; GÜL KANYILMAZ; BERRİN BENLİ YAVUZ

doi:10.56752/Mevmedsci.2024.57

MERYEM AKTAN,GÜL KANYILMAZ,BERRİN BENLİ YAVUZ

MERYEM AKTAN: NECMETTİN ERBAKAN ÜNİVERSİTESİ
GÜL KANYILMAZ: NECMETTİN ERBAKAN ÜNİVERSİTESİ
BERRİN BENLİ YAVUZ: NECMETTİN ERBAKAN ÜNİVERSİTESİ

Year : 2024
Vol : 4
Issue : 1
Page : 37-41

DOI : https://doi.org/10.56752/Mevmedsci.2024.57

Amaç: Tüm dünyada yaşlı nüfüsun artmasıyla rektum kanserli yaşlı hastaların sağkalımına etkileyen faktörlerrin incelenmesi amaçlandı.
Gereçler ve Yöntem: Aralık 2009- Haziran 2021 tarihleri arasında, 65 yaş üstü ve neoadjuvan KRT (nKRT) uygulanmış 171 hastanın verileri retrospektif olarak incelendi.
Bulgular: Çalışmaya dahil edilen hastaların 117 si erkekti ve median yaş 72 idi. Median izlem süresi 40,5 aydı. Hastaların %63 ü nKRT sonrası opere edildi. Ortalama genel sağkalım (GS) opere olanlarda 109 ay, opere olmayanlarda 29 ay idi (p<0,001). Kaplan Meier tek değişkenli analizlerde; yaş (<75 vs >75, p<0.00), Karnofsky Performans skalası (KPS, <70 vs>70, p=001), tanı anında lenf nodu durumu (LN+ vs LN-,p<0,001), opere olanlarda lenfovasküler invazyon durumu (LVI+ vs -, p<0,001) GS etkileyen faktörler olarak bulundu. Yaş gruplarına göre bakıldığında <75 yaşta operasyonun sağkalıma anlamlı katkısı varken (p<0,001), 75 yaş üstü hastalarda opere olup olmamanın sağkalıma katkısı gösterilemedi. Benzer şekilde >75 yaşta KPS nin anlamlı katkısı gösterilemedi.
Sonuç: Yaş ilerledikçe komorbid hastalıkların sık ve ağır seyretmesi ve performansı etkileyeceğinden operasyon durumunun sağkalıma etkisinin saptanamamış olabileceği düşünüldü.

Cite this Article As : Aktan M, Kanyilmaz G, Yavuz BB. Factors Affecting Survival in Elderly Rectum Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy. Mev Med Sci. 2024; 4(1): 37-41

Conflict of interest : The authors declare that they have no conflict of interest.

This article is published under the CC BY-NC 4.0 license.

Mevlana Tıp Bilimleri
2024, Vol4, Issue1
E-ISSN: 2757-976X

Received : 29.03.2024, Accepted : 24.04.2024 , Published Online : 26.04.2024

References

1. Arnold M, Sierra MS, Laversanne M, et.al. Global patterns and trends in colorectal cancer incidence and mortality. Gut 2017; 66: 683–691
2. Howlader N, Noone A, Krapcho M, et al. Cancer Statistics Review, 1975-2014 - SEER Statistics, National Cancer Institute. In: SEER Cancer Stat. Rev. 1975–2014. 2016.
3. Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203. J Clin Oncol. 2006;24:4620–4625.
4. Evrimler S, Kaymaz ZA, Diler H, et.al. The Role of Magnetic Resonance Imaging in The Evaluation of Response of The Locally Advanced Rectal Cancer to The Chemoradiotherapy. Selcuk Med J 2021;37(3): 209-217
5. Kanyılmaz G, Aktan M, Yavuz BB. Current Status of Pre-Operative Radiotherapy for Locally Advanced Rectal Cancer. Selcuk Med J 2020;36(1): 70-78
6. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–1740.
7. Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203. J Clin Oncol. 2006;24:4620–4625.
8. Sheikh AR, Yameen H, Hartshorn K. Treatment of Rectal Cancer in Older Adults, Current Oncology Reports (2018) 20: 102.
9. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Prz Gastroenterol 2019; 14: 89–103.
10. Edge SB, Byrd DR, Compton CC, et.al. AJCC Cancer Staging Manual. American Joint Committee. 7th ed. New York, NY: Springer; 2010.
11. Hofheinz RD, Wenz F, Post S, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: A randomized, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012;13:579-88.
12. Nishino M, Jagannathan JP, Ramaiya NH, et.al. Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know. AJR Am J Roentgenol 2010;195:281-9
13. CommonTerminologyCriteria forAdverse Events (CTCAE) — CTCAE 4.03 2010- 06-14 QuickReference 5x7.pdf n.d [Accessed 28 February 2017]
14. De Felice F, Crocetti D, Maiuri V, et al. Locally advanced rectal Cancer: treatment approach in elderly patients. Curr Treat Options Oncol 2020; 21:1.
15. Badic B, Oguer M, Cariou M, et.al. Ostomy prevalence and survival in elderly patients with stage III and IV rectal cancer. Badic B, Oguer M, Cariou M, et al. Ostomy prevalence and survival in elderly patients with stage III and IV rectal cancer. Geriatr. Gerontol. Int. 2021;21:670–675.
16. Montroni I, Ugolini G, Saur NM, et al. Personalized management of elderly patients with rectal cancer: expert recommendations of the European Society of Surgical Oncology, European Society of Coloproctology, International Society of Geriatric Oncology, and American College of Surgeons Commission on Cancer. Eur J Surg Oncol 2018; 44: 1685–1702.
17. Dekker JW, van den Broek CB, Bastiaannet E, et.al. Importance of the first postoperative year in the prognosis of elderly colorectal cancer patients. Ann Surg Oncol 2011; 18: 1533–1539
18. van der Valk MJM, Hilling DE, Bastiaannet E et.al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet 2018; 391: 2537–2545.
19. Sung SY, Jang HS, Kim SH, et.al. Oncologic Outcome and Morbidity in the Elderly Rectal Cancer Patients After Preoperative Chemoradiotherapy and Total Mesorectal Excision A Multi-institutional and Case-matched Control Study. Annals of Surgery 2019;269(1).